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Glycosylation of plasma IgG in 
colorectal cancer prognosis
Evropi Theodoratou1,2,*, Kujtim Thaçi3,*, Felix Agakov4, Maria N.  Timofeeva2, 
Jerko Štambuk3, Maja Pučić-Baković3, Frano Vučković3, Peter Orchard4, Anna Agakova4, 
Farhat V. N. Din2, Ewan Brown5, Pauline M. Rudd6, Susan M. Farrington2, Malcolm G. Dunlop2, 
Harry Campbell1,2,* & Gordan Lauc3,7,*
In this study we demonstrate the potential value of Immunoglobulin G (IgG) glycosylation as a novel 
prognostic biomarker of colorectal cancer (CRC). We analysed plasma IgG glycans in 1229 CRC patients 
and correlated with survival outcomes. We assessed the predictive value of clinical algorithms and 
compared this to algorithms that also included glycan predictors. Decreased galactosylation, decreased 
sialylation (of fucosylated IgG glycan structures) and increased bisecting GlcNAc in IgG glycan structures 
were strongly associated with all-cause (q < 0.01) and CRC mortality (q = 0.04 for galactosylation and 
sialylation). Clinical algorithms showed good prediction of all-cause and CRC mortality (Harrell’s C: 0.73, 
0.77; AUC: 0.75, 0.79, IDI: 0.02, 0.04 respectively). The inclusion of IgG glycan data did not lead to any 
statistically significant improvements overall, but it improved the prediction over clinical models for 
stage 4 patients with the shortest follow-up time until death, with the median gain in the test AUC of 
0.08. These glycan differences are consistent with significantly increased IgG pro-inflammatory activity 
being associated with poorer CRC prognosis, especially in late stage CRC. In the absence of validated 
biomarkers to improve upon prognostic information from existing clinicopathological factors, the 
potential of these novel IgG glycan biomarkers merits further investigation.
Colorectal cancer (CRC) is the 4th most commonly diagnosed cancer in UK (13% of all cancers) and the 2nd 
most common cause of cancer death (10% of total) (Cancer Research UK). The risk of recurrence and death from 
CRC is related to tumour stage at diagnosis. The growing repertoire of treatments available for CRC, includ-
ing new chemotherapy approaches, combined with challenging benefit:toxicity ratios and cost, highlights the 
importance of targeting interventions to patients most likely to benefit. Whilst clinico-pathological staging can 
stratify prognostic groups, it is limited in the precision with which it categorise poor/good prognosis tumours and 
informs treatment decisions at the individual level. This is clinically important, since patients with AJCC stage 
2 CRC may be offered adjuvant chemotherapy if their cancer is classified as high risk1. In practice, pathological 
staging provides practically useful categorical classifications, however, stage 2 and 3 cancers comprise a spec-
trum of both apparent pathological features and also aggressiveness and the ability to subsequently metastasise. 
Furthermore, currently available tumour biomarkers assayed in blood perform poorly in terms of sensitivity, 
greatly limiting their value in cancer prognosis2. Hence, improving the discriminatory performance of patholog-
ical staging offers much potential for clinical benefit.
Human cells are covered with a layer of carbohydrates or glycans called the glycocalyx3. Glycosylation of pro-
teins is an important post-translational modification for normal physiological processes such as protein folding, 
degradation and secretion and these changes are often instrumental in promoting cellular proliferation, inflam-
matory processes and metastasis4. There are several classes of glycans, including Asn (N)-linked and Ser/Thr 
(O)-linked glycans3. A number of different studies include preliminary reports of potentially important glycan 
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biomarkers for cancer and other diseases5–10. However, technical challenges in analysing complex glycan struc-
tures have, thus far, hindered large scale investigation in human studies4,11,12. Many known cancer biomarkers are 
glycoproteins, but diagnostic tests often only measure the protein fraction, despite the fact that in many cases it 
has been convincingly demonstrated that assays of glycosylation status significantly improve diagnostic value of 
such biomarkers13,14.
Immunoglobulins (Igs) are glycoprotein molecules made by plasma cells in response to challenge from anti-
gens such as those associated with microbiological agents or cancer cells and there have been previous reports 
that IgG antibodies can act as independent cancer prognostic factors15,16. Glycosylation is an important mod-
ulator of IgG function17,18. In this study, we explore the role of IgG glycosylation status as a novel prognostic 
biomarker of CRC, but also for classifying those patient groups with more aggressive tumours. This is the first 
large-scale investigation of the role of IgG N-glycans in cancer prognosis and is made possible by recent techno-
logical developments19.
We performed the first Genome Wide Association Study (GWAS) of the human IgG N-glycome and identi-
fied 9 single nucleotide polymorphisms (SNP) showing genome-wide association (p < 5 × 10−8)20. This included 
the IKZF1 locus, which has been reported to be associated with the risk of various cancers21 and appears to be a 
key regulator of IgG core-fucosylation. In addition, in a parallel IgG N-glycome study we observed substantial 
inter-individual variation in IgG glycosylation. The levels of IgG molecules without core-fucose varied between 
1.3% and 19% and we postulated that this may have a significant impact on antibody-dependent cellular cytotox-
icity (ADCC) and thus capacity to eliminate cancer cells22.
We have recently reported that CRC associates with decrease in IgG galactosylation, IgG sialylation and 
increase in core-fucosylation of neutral glycans with concurrent decrease of core-fucosylation of sialylated gly-
cans23. To examine the potential role of individual variation in IgG glycosylation on CRC prognosis we performed 
detailed characterisation of IgG glycome composition in 1229 CRC patients. In addition, we explored the prog-
nostic biomarker potential of IgG glycans after stage stratification to account for the different stage prognosis of 
CRC patients.
Results
IgG glycan measurements. The IgG glycan analysis resulted in 23 directly measured IgG glycans struc-
tures, and 54 derived traits that represent common features shared among several measured glycans (galactosyl-
ation, sialylation, core fucosylation and the incidence of bisecting GlcNAc; Fig. 1, Supplementary Table 1)22,24. 
We restricted our survival analysis to those IgG glycan traits that were found to be robustly analysed. Robustness 
was calculated as follows. On each plate from the CRC cohort we put 3 standards that were biologically identical. 
Therefore, differences between measurements of standards are consequence of only experimental noise. We then 
Figure 1. UPLC analysis of immunoglobulin G (IgG) glycosylation. Each IgG contains one conserved 
N-glycosylation site on Asn197 of its heavy chain. Different glycans can be attached to this site and the process 
seems to be highly regulated. UPLC analysis can reveal composition of the glycome attached to a population of 
IgG molecules by separating total IgG N-glycome into 24 chromatographic glycan peaks (GP1–GP24), mostly 
corresponding to individual glycan structures.
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calculated the variance of standards only and the variance in the whole CRC population. “Robustness” is defined 
as the ratio of those two variances (Var(Stand)/Var(CRC)) * 100 (i.e. lower values indicate higher robustness) and 
represents the contribution of experimental variation in total variation. Thirty nine of the 77 glycan traits whose 
percentage of experimental variation was below 20% were included in the analysis (Supplementary Table 1). The 
correlation coefficients of the robust measured and derived glycan traits are presented in Supplementary Fig. 1.
Survival analysis. Among the 1229 patients, there were 9563 person-years of follow-up. There were 489 
deaths, including 385 from CRC. Median follow-up was 9.4 years (IQR: 4.4 to 10.6 years) overall, and 10.3 years 
(IQR: 9.6 to 11.0 years) for live patients. Summary statistics and univariate Cox regression analysis for the con-
founding factors that were included in the subsequent glycan analysis are presented in Table 1. Of them stage 
at diagnosis and post-surgery CRP levels were strongly associated with all-cause and CRC-specific mortality 
(all-cause mortality: stage 3 vs. stage 1 OR (95% CI): 2.65 (1.96, 3.59), p-value 3.0 × 10−10; stage 4 vs. stage 1 OR 
(95% CI): 14.32 (10.37, 19.77), p-value 8.1 × 10−19; CRP levels > 10 mg/l vs. ≤ 10 mg/l OR(95% CI): 2.13 (1.67, 
2.72), p-value 1.1 × 10−9). Age at diagnosis, sex and site of cancer (colon or rectum) were not associated with 
all-cause or CRC-specific mortality.
The univariate glycan HRs for the whole sample complete case analysis are presented in Table 2 and 
Supplementary Table 2 for all-cause mortality and in Table 2 and Supplementary Table 3 for CRC specific 
mortality. IgG glycans linked to mainly galactosylation were strongly associated with all-cause mortality and 
CRC mortality. In particular an increase in the percentage of agalactosylated structures (G0n) and a decrease 
All-cause mortality Deceased Cases N = 489 Survived/Censored cases N = 740 p-value HR (95% CI) p-value
Mean age (SD) 59.94 (10.15) 58.59 (9.87) 0.02 1.01 (1.00, 1.02) 0.09
Sex
 Men 287 416 1.00
 Women 202 324 0.39 0.96 (0.80, 1.15) 0.67
AJCC stage
 1 54 195 1.00
 2 115 306 1.35 (0.98, 1.87) 0.07
 3 186 227 2.65 (1.96, 3.59) 3.0 × 10−10
 4 134 12 < 10−5 14.32 (10.37, 19.77) 8.3 × 10−19
Site
 Colon 263 430 1.00
 Rectum 223 304 0.12 1.14 (0.95, 1.36) 0.15
 Mean BMI (SD)a 26.86 (4.77) 26.32 (4.09) 0.05 1.03 (1.01, 1.05) 0.02
 Mean CRP (SD) 5.99 (14.24) 2.54 (8.88) < 10−5 1.02 (1.01, 1.02) 1.2 × 10−11
CRP
 ≤10 mg/l 412 687
 >10 mg/l 77 53 < 10−5 2.13 (1.67, 2.72) 1.1 × 10−9
CRC mortality Deceased Cases N = 385 Survived/Censored cases N = 844 p-value HR (95% CI) p-value
Mean age (SD) 58.81 (10.23) 59.27 (9.89) 0.46 1.00 (0.99, 1.01) 0.48
Sex
 Men 212 491 1.00
 Women 173 353 0.31 1.12 (0.91, 1.36) 0.28
AJCC stage
 1 22 227 1.00
 2 76 345 2.17 (1.35, 3.49) 0.001
 3 159 254 5.40 (3.46, 8.43) 1.3 × 10−13
 4 128 18 < 10−5 30.63 (19.38, 48.40) 1.2 × 10−48
Site
 Colon 205 488 1.00
 Rectum 178 349 0.12 1.16 (0.95, 1.42) 0.15
 Mean BMI (SD)a 27.08 (4.88) 26.29 (4.12) 0.007 1.04 (1.01, 1.06) 0.002
 Mean CRP (SD) 6.57 (15.24) 2.71 (8.98) < 10−5 1.02 (1.01, 1.03) 4.5× 10−12
CRP
≤10 mg/l 318 781 1.00
>10 mg/l 67 63 < 10−5 2.37 (1.82, 3.09) 1.4 × 10−10
Table 1. Summary statistics and univariate Cox regression for factors influencing all-cause and CRC 
mortality. aBMI available for 1057 CRC cases (415 all-cause deaths and 642 survived/censored).
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in mono- and di-galactosylated structures (G1n, G2n) was associated with poorer all-cause and CRC-specific 
mortality. Statistically significant associations were also observed for decreased sialylation and increase in the 
incidence of bisecting GlcNAc (Table 2). Results were similar when AJCC stage 4 patients were excluded from the 
analysis (Supplementary Tables 4 and 5). The minus logarithm of the q-values (FDR corrected p-values) of all 39 
glycan traits for all-cause mortality and CRC-specific model III are presented in a Manhattan-like plot (Fig. 2).
Glycan
ALL cause analysis CRC-specific analysis
Dead Survived Model II (AJCC, age, sex,
time between sample and surgery, 
operation type, BMI, CRP, n = 952)
Dead Survived Model II (AJCC, age, sex,
time between sample and surgery, 
operation type, CRP, bmi, n = 971)(N = 489) (N = 740) (N = 385) (N = 844)
Mean (SD) Mean (SD) HR (95% CI) p-value q-value Mean (SD) Mean (SD) HR (95% CI) p-value q-value
Total IgG glycans (neutral and charged); Measured
 GP4 26.39 (7.33) 23.87 (6.37) 1.28 (1.14, 1.43) 2.6 × 10−5 0.0008 26.20 (7.31) 24.27 (6.59) 1.23 (1.09, 1.40) 0.001 0.04
 GP6 6.34 (1.88) 5.79 (1.57) 1.19 (1.06, 1.34) 0.002 0.05 6.23 (1.85) 5.91 (1.63) 1.10 (0.97, 1.25) 0.14 0.99
 GP8 18.26 (2.21) 18.67 (1.81) 0.87 (0.78, 0.97) 0.01 0.18 18.33 (2.13) 18.59 (1.91) 0.92 (0.81, 1.04) 0.16 0.99
 GP9 9.38 (1.36) 9.83 (1.35) 0.83 (0.75, 0.92) 0.0003 0.009 9.46 (1.35) 9.74 (1.38) 0.90 (0.80, 1.01) 0.06 0.99
 GP10 5.45 (1.23) 5.48 (1.15) 0.93 (0.84, 1.04) 0.2 0.74 5.40 (1.19) 5.50 (1.18) 0.90 (0.80, 1.02) 0.11 0.99
 GP11 10.19 (3.13) 11.44 (3.13) 0.77 (0.68, 0.86) 9.6× 10−6 0.0004 10.30 (3.19) 11.24 (3.15) 0.81 (0.71, 0.92) 0.002 0.06
 GP15 1.38 (0.41) 1.50 (0.43) 0.86 (0.77, 0.96) 0.007 0.133 1.38 (0.40) 1.49 (0.43) 0.86 (0.76, 0.98) 0.02 0.46
 GP18 7.78 (2.29) 8.47 (2.34) 0.79 (0.71, 0.89) 4.9× 10−5 0.002 7.87 (2.31) 8.35 (2.34) 0.82 (0.72, 0.93) 0.002 0.06
 GP19 1.87 (0.38) 1.90 (0.39) 0.98 (0.89, 1.08) 0.7 0.74 1.87 (0.37) 1.90 (0.39) 1.00 (0.90, 1.12) 0.98 0.99
Sialylation; Derived
 FGS/(FG+ FGS) 24.78 (3.20) 24.95 (3.10) 0.93 (0.84, 1.03) 0.18 0.74 24.84 (3.24) 24.90 (3.09) 0.90 (0.80, 1.01) 0.08 0.99
 FBGS/(FBG+ FBGS) 32.83 (6.17) 32.58 (6.34) 1.04 (0.94, 1.15) 0.47 0.74 32.93 (6.13) 32.56 (6.34) 1.05 (0.94, 1.19) 0.38 0.99
 FGS/(F+ FG+ FGS) 16.35 (3.63) 17.35 (3.61) 0.81 (0.72, 0.90) 0.0001 0.003 16.47 (3.64) 17.17 (3.63) 0.82 (0.72, 0.92) 0.001 0.04
 FBGS/(FB+ FBG+ FBGS) 21.21 (4.88) 21.82 (4.96) 0.95 (0.86, 1.05) 0.3 0.74 21.38 (4.93) 21.66 (4.94) 0.99 (0.88, 1.11) 0.8 0.99
 FG2S1/(FG2+ FG2S1+ FG2S2) 40.18 (2.99) 39.51 (2.77) 1.06 (0.95, 1.18) 0.28 0.74 40.22 (3.05) 39.57 (2.77) 1.00 (0.89., 1.13) 0.99 0.99
 FBG2S1/(FBG2+ FBG2S1+ FBG2S2) 37.02 (3.87) 36.41 (3.97) 1.12 (1.01, 1.24) 0.03 0.51 37.11 (3.80) 36.44 (3.99) 1.17 (1.04, 1.31) 0.009 0.25
Bisecting GlcNAc; Derived
 FBStotal/FStotal 0.30 (0.08) 0.28 (0.07) 1.19 (1.06, 1.33) 0.002 0.05 0.30 (0.07) 0.29 (0.08) 1.17 (1.03, 1.33) 0.02 0.46
 FBS1/FS1 0.17 (0.05) 0.16 (0.05) 1.18 (1.06, 1.32) 0.003 0.07 0.17 (0.05) 0.16 (0.05) 1.19 (1.05, 1.35) 0.006 0.17
 FBS1/(FS1+ FBS1) 0.14 (0.04) 0.14 (0.03) 1.19 (1.06, 1.32) 0.002 0.05 0.14 (0.03) 0.14 (0.03) 1.19 (1.06, 1.35) 0.005 0.15
 FBS2/FS2 1.35 (0.32) 1.27 (0.30) 1.17 (1.05, 1.31) 0.005 0.11 1.33 (0.32) 1.29 (0.30) 1.10 (0.98, 1.25) 0.12 0.99
 FBS2/(FS2+ FBS2) 0.56 (0.06) 0.55 (0.06) 1.17 (1.05, 1.30) 0.005 0.11 0.56 (0.06) 0.55 (0.06) 1.10 (0.97, 1.25) 0.13 0.99
Neutral IgG glycans; Measured
 GP4n 32.33 (8.02) 29.56 (7.02) 1.28 (1.14, 1.43) 2.6× 10−5 0.0008 32.14 (8.00) 29.98 (7.24) 1.24 (1.09, 1.41) 0.001 0.04
 GP6n 7.78 (2.07) 7.18 (1.76) 1.17 (1.05, 1.31) 0.006 0.12 7.65 (2.07) 7.31 (1.83) 1.08 (0.94, 1.22) 0.27 0.99
 GP8n 22.59 (3.09) 23.32 (2.52) 0.83 (0.74, 0.92) 0.001 0.028 22.71 (3.01) 23.18 (2.66) 0.87 (0.77, 0.98) 0.02 0.46
 GP9n 11.60 (1.81) 12.28 (1.75) 0.79 (0.71, 0.88) 1.5× 10−5 0.0005 11.72 (1.81) 12.14 (1.79) 0.85 (0.76, 0.97) 0.01 0.26
 GP10n 6.73 (1.54) 6.85 (1.46) 0.90 (0.81, 1.01) 0.06 0.74 6.68 (1.49) 6.85 (1.50) 0.88 (0.77, 0.99) 0.03 0.66
 GP14n 12.70 (4.29) 14.39 (4.37) 0.76 (0.68, 0.86) 7.4× 10−6 0.0003 12.86 (4.38) 14.11 (4.38) 0.80 (0.71, 0.92) 0.001 0.04
 GP15n 1.72 (0.54) 1.89 (0.59) 0.85 (0.76, 0.95) 0.003 0.07 1.72 (0.53) 1.87 (0.59) 0.85 (0.75, 0.97) 0.01 0.26
Galactosylation; Derived
 G0n 41.15 (9.19) 37.69 (8.09) 1.31 (1.16, 1.47) 5.5× 10−6 0.0002 40.83 (9.18) 38.26 (8.36) 1.24 (1.09, 1.41) 0.001 0.04
 G1n 42.72 (4.71) 44.26 (3.56) 0.78 (0.69, 0.87) 1.3× 10−5 0.0005 42.90 (4.63) 43.99 (3.83) 0.82 (0.72, 0.94) 0.003 0.09
 G2n 15.65 (5.00) 17.61 (5.15) 0.78 (0.69, 0.87) 2.4× 10−5 0.0008 15.79 (5.09) 17.30 (5.16) 0.81 (0.71, 0.93) 0.002 0.06
Core fucosylation and bisecting GlcNAc; Derived
 Fn 79.47 (3.74) 79.77 (3.46) 0.96 (0.86, 1.07) 0.48 0.74 79.68 (3.70) 79.63 (3.52) 1.02 (0.90, 1.15) 0.77 0.99
 FG0n/G0n 78.81 (4.29) 78.69 (4.11) 1.04 (0.93, 1.16) 0.46 0.74 79.01 (4.23) 78.62 (4.16) 1.10 (0.97, 1.24) 0.13 0.99
 FG1n/G1n 80.03 (3.79) 80.45 (3.56) 0.94 (0.85, 1.05) 0.31 0.74 80.24 (3.73) 80.30 (3.62) 1.00 (0.89, 1.14) 0.94 0.99
 FBn 17.29 (3.20) 16.97 (2.90) 1.02 (0.91, 1.14) 0.73 0.74 17.10 (3.15) 17.09 (2.97) 0.95 (0.84, 1.08) 0.44 0.99
 FBG0n/G0n 19.15 (3.88) 19.30 (3.65) 0.94 (0.84, 1.05) 0.25 0.74 18.98 (3.81) 19.36 (3.70) 0.89 (0.79, 1.01) 0.07 0.99
 FBG1n/G1n 18.20 (3.46) 17.82 (3.25) 1.04 (0.93, 1.16) 0.5 0.74 18.01 (3.39) 17.96 (3.32) 0.97 (0.86, 1.10) 0.64 0.99
 FBn/Fn 0.22 (0.05) 0.21 (0.05) 1.02 (0.92, 1.14) 0.68 0.74 0.21 (0.05) 0.21 (0.05) 0.95 (0.84, 1.08) 0.47 0.99
 FBn/Fn total 17.88 (3.38) 17.55 (3.07) 1.02 (0.92 , 1.14) 0.68 0.74 17.68 (3.33) 17.68 (3.14) 0.96 (0.85, 1.09) 0.5 0.99
 Fn/(Bn + FBn) 4.65 (1.09) 4.71 (1.01) 0.98 (0.88, 1.09) 0.74 0.74 4.71 (1.06) 4.68 (1.03) 1.05 (0.92, 1.18) 0.47 0.99
Table 2. All cause and CRC-specific analysis for rank transformed glycans. Q value represents the adjusted 
p-values using the false discovery rate method (Benjamini–Hochberg procedure).
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Stratified analysis by stage for all-cause and CRC-specific mortality is presented in Supplementary Tables 
6 and 7. An increase in the percentage of agalactosylated structures (G0n) and a decrease in mono- and 
di-galactosylated structures (G1n, G2n) was associated with poorer all-cause and CRC-specific mortality in stages 
1, 2 and 3 (p-values from all-cause mortality models for G0n: stage 1: 0.05, stage 2: 0.009 and stage 3: 0.01) but 
not in stage 4 (p-value for G0n: 0.38). In contrast, decrease in sialylation and increase in incidence of bisect-
ing GlcNAc were statistically significantly associated with all-cause and CRC-specific mortality only in stage 
4 (p-values from all-cause mortality models for stage 4 for FGS/(FG + FGS): 0.003; FGS/(F + FG + FGS): 0.01; 
FG2S1/(FG2 + FG2S1 + FG2S2): 0.002; FBG2S1/(FBG2 + FBG2S1 + FBG2S2): 0.008; FBS1/FS1: 0.008). Finally, 
only in stage 2 disease IgG glycans linked to core fucosylation were associated with all-cause and CRC-specific 
mortality (Supplementary Tables 6 and 7).
Multivariate Cox regression clinical algorithms (including all the covariates of model III) showed good pre-
diction of subsequent all cause (Harrell’s C = 0.73, AUC = 0.75, IDI = 0.02 [as compared to model II that included 
AJCC stage, age and sex]) and CRC-mortality (Harrell’s C = 0.77, AUC = 0.79, IDI = 0.04 [as compared to model 
II that included AJCC stage, age and sex]). Using glycans in addition to the clinical factors (that were selected by 
generalised boosted regression) did not lead to any statistically significant improvements for the whole sample 
analysis (Table 3) or after stage stratification (Supplementary Tables 8 and 9). This was reconfirmed by using 
Cox regression with L1 (LASSO) penalties on model parameters25, as there were no significant differences in the 
validation deviances of models with and without glycans both for the whole sample and stage-stratified designs. 
Similarly, predictions of the 5-year risk of death using the clinical factors stage, age, sex, BMI and CRP (e.g. 
Figure 2. Manhattan-type plot of the association FDR corrected p values (q-values) of all 39 glycan 
variables for all–cause (red dots) and CRC-specific (blue dots) mortality adjusted for AJCC CRC stage, age, 
sex, time between sample and surgery, operation type, CRP and BMI (Model II). Analysed glycans are plotted 
on the X-axis. Y-axis plots the – logarithm of the q values. The names of glycans, which associations achieved 
statistical significance after correction for multiple testing (q < 0.05), are named in the plot. Details of the 
association analysis results are presented in Table 2 and cartoon structures of the glycans are presented in Fig. 1.
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AUC = 0.80, Positive Predictive Value [PPV or precision] = 0.80, using the Naïve Bayes classifier with a kernel 
density estimator for the marginal distributions) were not improved by the addition of glycans data to the clinical 
factors. We refer the reader to the Supplementary Tables 10 and 11 and the Supplementary Section on Model 
Comparison for discussions and explanations.
When we stratified by stage, adding glycans to the clinical variables improved the prediction results, did 
not change them, or made them worse, depending on the stage of cancer and on the chosen models. We tested 
whether independently of the choice of a model class, adding glycans to clinical covariates would improve pre-
dictions of a model of the same class estimated on independent test data using cross-validation. We performed 
two instances of the paired Wilcoxon sign-rank test comparing models with and without glycans, including all 
the considered models (W), or including only the models of disparate classes (Wd) as discussed in Methods. We 
showed that there was no significant improvement in the prediction of the rapid progressors using glycans (in 
addition to the clinical factors) for stage 2 (pW ~ 0.99, pWd ~ 0.98) as measured by cumulative (merged) AUC on 
the validation data (Supplementary Table 12). Similarly, for stage 3 the impact of the glycans was not consistent 
across the models, varied depending on the modelling assumptions, and was not significant overall (pW ~ 0.75, 
pWd ~ 0.58; Supplementary Table 13).
On the other hand, there was a significant improvement in the prediction of the rapid progressors using gly-
cans for stage 4 (Supplementary Table 14), with pW ~ 0.01, pWd ~ 0.04, leading to the median gain in the test AUC 
of 0.08. Importantly, the inclusion of glycans in the models consistently resulted in the improved quality of pre-
dictions across the range of the considered models, and independently of whether the restricted or extended sets 
of clinical variables were used in the adjustments. The results were qualitatively similar for multiple repetitions of 
10-fold cross-validation with random partitions into non-overlapping test folds, and independently of whether 
10-fold or two-fold cross-validation was used to estimate the AUC on test data for the considered models. The 
best extended clinical model had the test AUC of 0.58, with the PPV of 0.35. The best model augmented with 
unfiltered log-transformed glycans had the test AUC of 0.66, with the PPV of 0.62. (Note: we acknowledge that 
since the choice of these best models uses the validation data, new external validations are needed to confirm the 
differences).
Clinical algorithm
All-cause mortality
Clinical algorithm
CRC mortality
HR (95% CI) p-value HR (95% CI) p-value
Age 1.03 (1.01–1.04) 9.2 × 10−6 Age 1.02 (1.00–1.03) 0.02
Sex 0.91 (0.74–1.12) 0.36 Sex 1.03 (0.82–1.29) 0.82
AJCC stage 2 vs 1 1.30 (0.92–1.83) 0.14 AJCC stage 2 vs 1 2.22 (1.33–3.72) 0.002
AJCC stage 3 vs 1 2.44 (1.77–3.38) 7.3 × 10−8 AJCC stage 3 vs 1  5.02 (3.09–8.15) 6.7 × 10−11
AJCC stage 4 vs 1 15.92 (11.16–22.70) < 2.0 × 10−16 AJCC stage 4 vs 1 34.05 (20.60–56.29) < 2.0 × 10−16
CRP 1.96 (1.47–2.62) 4.9 × 10−6 CRP  2.08 (1.52–2.86) 4.8 × 10−6
BMI 1.04 (1.01–1.06) 0.002 BMI  1.05 (1.02–1.08) 0.0001
Harrell’s C 0.73 Harrell’s C 0.77
IDIa 0.02 IDIa 0.04
AUC 0.74 AUC 0.79
Clinical/glycans 
algorithm
All-cause mortality Clinical/glycans 
algorithm
CRC mortality
HR (95% CI) p-value HR (95% CI) p-value
Age 1.02 (1.01–1.03) 0.003 Age  1.01 (0.99–1.02) 0.28
Sex 0.91 (0.74–1.12) 0.36 Sex 1.04 (0.82–1.30) 0.77
AJCC stage 2 vs 1 1.33 (0.94–1.88) 0.11 AJCC stage 2 vs 1  2.24 (1.34–3.74) 0.002
AJCC stage 3 vs 1 2.49 (1.80–3.45) 4.1 × 10−8 AJCC stage 3 vs 1  5.01 (3.09–8.14) 7.1 × 10−11
AJCC stage 4 vs 1 15.72 (10.99–22.49) < 2.0 × 10−16 AJCC stage 4 vs 1  33.63 (20.18–56.04) < 2.0 × 10−16
CRP 1.66 (1.23–2.25) 0.001 CRP  1.84 (1.31–2.59) 0.0004
BMI 1.03 (1.01–1.06) 0.006 BMI  1.05 (1.02–1.07) 0.0007
IGP48  1.69 (0.64–4.47) 0.29 IGP29 0.92 (0.81–1.05) 0.21
IGP26  0.72 (0.55–0.95) 0.02 IGP13  0.85 (0.74–0.97) 0.01
IGP8 0.53 (0.21–1.30) 0.16 IGP8  0.91 (0.81–1.03) 0.14
Harrell’s C 0.73 Harrell’s C 0.77
IDIb 0.05 IDIb 0.03
AUC 0.75 AUC 0.79
Table 3. Multivariate Cox regression of the a) clinical parameters and b) clinical and glycan parameters. 
aThe IDI was calculated based on the comparison of model II (adjusted for stage, sex and age) and the full 
clinical model III (adjusted for stage, age, sex, bmi and CRP – presented here). bThe IDI was calculated based 
on the comparison of the full clinical model III (adjusted for stage, age, sex, bmi and CRP) and the full clinical 
model III with the three top selected glycans.
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Discussion
In this study, we investigated the relationship between the IgG glycome composition in plasma from of CRC 
patients with survival outcomes. We applied univariate and multivariate statistical models to examine the asso-
ciations between specific glycan changes and CRC-specific or all-cause mortality. IgG glycans linked to galacto-
sylation, sialylation and bisecting GlcNAc were strongly associated with all-cause mortality and CRC mortality. 
Since the method used to analyse glycans normalises measured data to the total glycome, this effectively measures 
glycome content per molecule of IgG and is not sensitive to changes in total IgG concentration. Multivariate Cox 
regression clinical algorithms showed good prediction of outcome for all cause and CRC-mortality, but using 
glycans in addition to the clinical factors did not lead to any statistically significant improvements. However, 
when we investigated the prediction of rapid progressors within each AJCC stage, there was an improvement in 
the prediction of the rapid progressors using glycans for stage 4.
It is well established that glycosylation changes are involved in the aetiology of cancer, and specifically mark 
tumour proliferation and metastasis26. IgG is produced and secreted by CRC cells and the expression levels of 
CRC-tumour derived IgG correlated with clinical and pathological characteristics of the tumour (including 
stage)27. In particular it has been shown that expression of IgG was stronger in CRC tissues with TNM stage III–IV, 
than in those with TNM I–II. Similarly, in this study we observe different changes in IgG glycosylation status 
(levels of sialylation and incidence of bisecting GlcNAC) in late-stage disease and we see an improvement in the 
prediction algorithms using glycans in addition to clinical factors in AJCC stage 4.
IgG biological activity is influenced by its Fc-glycosylation. Each heavy chain of IgG carries a single covalently 
attached bi-antennary N-glycan at the highly conserved asparagine 297 residue in each of the CH2 domains of 
the Fc region of the molecule. The attached oligosaccharides are structurally important for the stability of the anti-
body and its effector functions28. In addition, 15–20% of normal IgG molecules also bear complex bi-antennary 
oligosaccharides attached to the variable regions of the light chain, heavy chain or both18,29.
Changes in IgG galactosylation, sialylation, bisecting GlcNaC and fucosylation have been previously reported 
in cancer studies (Supplementary Table 15). In particular, a decline in plasma IgG galactosylation has been 
observed in multiple myeloma, prostate, gastric, lung and ovarian cancers30–37. Previous studies investigated small 
sample sizes (< 100 cancer cases). This is the first time that similar changes in IgG galactosylation have been 
shown to be associated with CRC prognosis in a study with > 1000 CRC patients (Supplementary Table 15). It has 
been shown that the immune system can identify and destroy new tumour cells through cancer immunosurveil-
lance, which functions as an important defence against cancer. A recent review on the natural innate and adaptive 
immunity to cancer has presented evidence from mouse models that B cells (which create and release IgG) are 
important in the surveillance of CRC38. Furthermore, it has been hypothesised that decreased IgG galactosylation 
leads to a greater pro-inflammatory antibody response39,40, which might influence cancer survival after diagnosis. 
Interestingly, galactosylation of IgG increases during pregnancy and reverts to normal levels after delivery, indi-
cating that IgG glycome composition is prone to natural modifications41.
Similar to galactosylation, decreased sialylation of IgG also results in a pro-inflammatory IgG phenotype40. 
In this study we found that decreased sialylation was also linked to poorer prognosis, which replicated findings 
of two small studies on ovarian37 and gastric cancer33. However, there was conflicting evidence in a study of 
multiple myeloma42, where increased sialylation of IgG was linked to higher risk of multiple myeloma. Therefore, 
through both decreased galactosylation and decreased sialylation, IgG in CRC patients with poorer prognosis had 
significantly greater pro-inflammatory properties (decreased galactosylation and sialylation) than CRC patients 
with better prognosis. Furthermore elevated occurrence of bisecting GlcNAc and lack of core fucose results in 
increased ADCC activity. In our study we found higher occurrence of bisecting GlcNAc in CRC patients of 
poorer prognosis, but IgG core fucosylation changes were associated with all-cause or CRC-specific mortality 
only in stage 2 CRC patients.
To our knowledge, this is the largest study to date examining the complexities of IgG glycan structure in 
relation to CRC prognosis. It includes prospective CRC cases from almost all hospitals in Scotland therefore is 
broadly representative of the colorectal cancer population. Cases were recruited as soon as possible after diagnosis 
to limit survival bias among those recruited and maximize the person-years of follow up. In addition, data rele-
vant to the survival analysis were obtained from the Scottish registries General Register Office and the Scottish 
Cancer Registry (which are known to have high levels of data quality and data completeness) after linkage of 
our participants with their databases using the Community Health Index number. In addition, care was taken to 
determine the AJCC stage by experienced study clinicians reviewing individual computerized tomography scans 
and staging and metastasis information for every case. Information on date of diagnosis, date of sample taken 
and date of operation were collected and used in the univariate and multivariate models. Finally, we applied the 
state-of-the-art technology to measure the IgG glycosylation status in collaboration with the most experienced 
glyco-analytical laboratories in Europe.
This study has some limitations. One single measurement of IgG glycosylation status was taken after colorectal 
cancer diagnosis. Protein glycosylation status changes through time and is affected by factors such as age, oper-
ation and obesity. We have adjusted our analyses for all these factors, but it remains possible that glycosylation 
changes observed at the time of diagnosis do not reflect the glycosylation status at the time of death. This might 
also explain why IgG glycosylation status had more predictive power for late stage disease (since measurements 
were taken close to the end-event). However, the aim of this current work was to identify glycosylation changes 
that occur at colorectal cancer diagnosis and also investigate whether a measurement at time of diagnosis can act 
as a prognosis biomarker and therefore any biases due to single measurements are not relevant for these hypoth-
eses. The stratified analysis leads to a reduction in the sample size, which may adversely affect the quality of the 
constructed predictive models. Finally, since our analysis included CRC patients of Scottish origin only, it may be 
possible that these findings will not be applicable to other ethnic groups. However, we have recently analysed the 
IgG glycosylation in 3 independent cohorts of Systemic Lupus Erythematosus (SLE) patients of different ethnicity 
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and we observed very similar changes in IgG glycome composition in African Caribbean, Han Chinese, and Latin 
American Mestizo SLE patients despite known differences in SLE manifestation in different ethnic groups43. 
Therefore, there is a good reason to believe that the IgG glycosylation changes we observed in relation to CRC 
prognosis would be relevant to other ethnic populations too.
Some of the classification methods considered in this paper can be improved for handling imbalanced distri-
butions of class labels. We are currently developing such extensions based on the advancements in imbalanced 
classification44, with the specific focus on predicting the prognosis for patients diagnosed at stages 1 and 2. The 
predictions may potentially be improved further by adapting recent approaches based on interaction networks45 
of glycans and clinical factors. The definition of rapid progressors may require a refinement, especially at the 
earlier stages of colon cancer. For example, at stage 1, rather than defining a rapid progressor to be someone who 
dies of CRC during the lowest tertile of the follow-up, it could be useful to consider the speed of progression to the 
more advanced stages. We are currently investigating a range of alternative definitions. However, the key finding 
of IgG gyclans as a predictor of rapid CRC progression at the later stages remains potentially of great importance 
and should ideally be replicated in an independent study population.
The plasma IgG glycan differences which we observed at the time of CRC diagnosis are consistent with sig-
nificantly increased IgG pro-inflammatory activity being associated with poorer CRC prognosis, especially in 
late stage (stages 3 and 4) CRC. In the absence of validated biomarkers to improve upon prognostic informa-
tion from existing clinicopathological factors the potential of these novel IgG glycan biomarkers merits further 
investigation. In particular, the improved predictive power in models including glycan factors in stage 4 patients 
is interesting. Currently, there are various strategies that are employed when using chemotherapy46 in stage 4 
disease. Therefore having a novel biomarker or prediction model that could help select patient groups that may 
have a better prognosis and a more indolent disease course would be useful as these patients could perhaps be 
offered chemotherapy agents with lower toxicity when compared to a more aggressive combination strategy. 
Furthermore, there is a great interest in novel immunotherapies in cancer and therefore it will be of useful to iden-
tify a more ‘immunogenic’ tumour phenotype based on identified IgG glyco-markers with a particular response 
to immunotherapy. Certainly to date the most encouraging results for immunotherapies (including PD-1 inhib-
itors) have been in tumours such as melanoma that are thought to be highly immunogenic and there is further 
interest in investigating mismatch repair deficient colon cancers which are often associated histologically with a 
heavy immune infiltrate. Finally, recent studies47 demonstrated that IgG glycosylation changes are very dynamic 
and variable between individuals, thus longitudinal studies are needed to fully investigate the prognostic potential 
of IgG glycosylation changes in CRC.
Methods
Study population. The SOCCS study (1999–2006) is a case-control study designed to identify genetic and 
environmental factors associated with non-hereditary colorectal cancer risk and survival outcome. Approval for 
the study was obtained from the MultiCentre Research Ethics Committee for Scotland and Local Research Ethics 
committee, and all participants gave written informed consent. The study has been described in detail elsewhere48.
The present study comprises 1229 patients with pathologically confirmed colorectal adenocarcinoma, in 
whom we assayed IgG glycan levels after CRC diagnosis. Participants completed a detailed lifestyle questionnaire 
and a semi-quantitative food frequency and supplements questionnaire (http://www.foodfrequency.org). Blood 
was collected and transferred to the research centre within 72 h of sampling. Plasma was prepared by gentle 
ficoll hypaque gradient centrifugation of sodium EDTA tubes and 1.5 mL of each participant’s plasma was stored 
at − 80 °C.
IgG glycans measurement and normalisation. All methods for IgG glycans measurement and nor-
malisation were carried out in accordance with the approved guidelines as described as described previously24.
Purification of IgG: The IgG was isolated from plasma samples using 96-well protein G monolithic plates (BIA 
Separations, Ajdovščina, Slovenia). Briefly, 50–90 μ l of plasma was diluted 10× with 1× PBS, pH 7.4 and applied 
to the protein G plate. IgG was eluted with 0.1 M formic acid (v = 1 mL; Merck, Darmstadt, Germany) and neu-
tralized with 1 M ammonium bicarbonate (Merck).
Release and labelling of IgG glycans was performed as described previously22. IgG was first denatured with the 
addition of 30 μ L 1.33% SDS (w/v) (Invitrogen, Carlsbad, CA, USA) and 10 min incubation at 65 °C. Subsequently, 
10 μ L of 4% Igepal-CA630 (Sigma-Aldrich, St. Louis, MO, USA) and 1.25 mU of PNGase F (ProZyme, Hayward, 
CA, USA) in 10 μ L 5× PBS were added to the samples and incubated overnight at 37 °C to release N-glyans. The 
released N-glycans were labelled with 2-aminobenzamide (2-AB). The labelling mixture was freshly prepared 
by dissolving 2-AB (Sigma-Aldrich) in DMSO (Sigma-Aldrich) and glacial acetic acid (Merck) mixture (85:15, 
v/v) to a final concentration of 48 mg/mL. A volume of 25 μ L of labelling mixture was added to each N-glycan 
sample in the 96-well plate. Also, 25 μ L of freshly prepared reducing agent solution (106.96 mg/ml 2-picoline 
borane (Sigma-Aldrich) was added and the plate was sealed using adhesive tape. Mixing was achieved by shaking 
for 10 min, followed by 2 hour incubation at 65 °C. Samples (in a volume of 100 μ L) were brought to 80% ACN 
(v/v) by adding 400 μ L of ACN (J.T. Baker, Phillipsburg, NJ, USA). Free label and reducing agent were removed 
from the samples using HILIC-SPE. An amount of 200 μ L of 0.1 g/mL suspension of microcrystalline cellulose 
(Merck) in water was applied to each well of a 0.45 μ m GHP filter plate (Pall Corporation, Ann Arbor, MI, USA). 
Solvent was removed by application of vacuum using a vacuum manifold (Millipore Corporation, Billerica, MA, 
USA). All wells were prewashed using 5× 200 μ L water, followed by equilibration using 3× 200 μ L acetonitrile/
water (80:20, v/v). The samples were loaded to the wells. The wells were subsequently washed 7× using 200 μ L 
acetonitrile/water (80:20, v/v). Glycans were eluted with 2× 100 μ L of water and combined eluates were stored at 
−20 °C until usage.
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Hydrophilic Interaction Chromatography (HILIC)-UPLC: Fluorescently labelled N-glycans were separated by 
HILIC on a Waters Acquity UPLC instrument (Milford, MA, USA) with fluorescence detector set with excitation 
and emission wavelengths of 330 and 420 nm, respectively. The instrument was under the control of Empower 2 
software, build 2145 (Waters, Milford, MA, USA). Labelled N-glycans were separated on a Waters BEH Glycan 
chromatography column, 100× 2.1 mm i.d., 1.7 μ m BEH particles, with 100 mM ammonium formate, pH 4.4, 
as solvent A and acetonitrile as solvent B. Separation method used linear gradient of 75–62% acetonitrile (v/v) 
at flow rate of 0.4 ml/min in a 25 min analytical run. Samples were maintained at 5 °C before injection, and the 
separation temperature was 60 °C. The system was calibrated using an external standard of hydrolyzed and 2-AB 
labelled glucose oligomers from which the retention times for the individual glycans were converted to glucose 
units. Data processing was performed using an automatic processing method with a traditional integration algo-
rithm after which each chromatogram was manually corrected to maintain the same intervals of integration for all 
the samples. The chromatograms were all separated in the same manner into 24 peaks. In addition to 24 directly 
measured glycan structures, 53 derived traits were calculated as described previously22. These derived traits aver-
age particular glycosylation features (galactosylation, fucosylation, sialylation) across different individual glycan 
structures. Consequently, they are more closely related to individual enzymatic activities, and underlying genetic 
polymorphisms.
Glycan normalisation: Normalization of glycan measurements across samples, was performed by total area 
of chromatograms, where peak area of each glycan was divided by total area of corresponding chromatogram.
Survival and risk related parameters. Mortality outcomes were ascertained through linkage with the 
National Records of Scotland. Primary cause of death (“CRC” or “other”) was assigned from death certificates 
separately by two researchers (concordance was > 99%). Time to event was measured from the date of diagnosis. 
Survival follow-up was censored at the date of death or at January, 31 2013, for participants who were not known 
to have died. Clinicopathological staging data was collected where possible (e.g. TNM is not feasible in patients 
who did not undergo surgery). Clinical records were reviewed and tumour site and multiplicity were determined 
from clinical and pathological records. Pre-operative staging imaging was collected through participating cen-
tres. Using the collated pathology, imaging and clinical data, tumour stage was assigned according TNM staging 
system and mapped onto the American Joint Committee on Cancer (AJCC) tumour-node-metastasis system 
(AJCC 1–4).
Blood was collected after CRC diagnosis (and after surgery). Median time to sampling was 5.4 months after 
the diagnosis (interquartile range, IQR: 3.2 to 8.3 months). Since illness and treatment may acutely affect IgG gly-
can levels and confound the analysis, a variable describing time from operation to blood collection and a variable 
determining the type of operation were created.
Statistical analysis. Data were analysed using STATA (version 12.0) and R. We initially examined the asso-
ciation between IgG glycan levels (continuous and rank transformed) and CRC/all-cause mortality using Cox 
proportional hazards models. The non-CRC cause of death was right censored in CRC related mortality analysis. 
Tests of the proportional hazards assumptions and linearity on the log hazard rate scale were performed prior the 
analysis. Deviation from the proportional hazard assumption was noted for stage of disease variable in the overall 
analysis. No violation of assumption for any of the covariates was observed after stage stratification. Three models 
were applied in the whole dataset, in a dataset excluding stage 4 disease (to evaluate the glycan associations among 
patients with no-metastatic disease – AJCC stages 1–3): a crude model (Model I), a model where hazard ratios 
(HR) were adjusted for age at diagnosis, sex and stage of disease (Model II) and a model where HRs were adjusted 
for age at diagnosis, sex, stage of disease, body mass index (BMI), time from operation to blood collection, type 
of operation and CRP (Model III). P-values were adjusted for multiple testing using false discovery rate method 
(Benjamini–Hochberg procedure). Then we investigated whether the profiles of biomarkers differed across the 
stages of CRC by performing AJCC stage stratification.
We estimated the predictive value of a clinical-only Cox-regression algorithm for model II (which included 
age, sex, disease stage) and model III (which was adjusted for age, sex, disease stage, BMI and CRP level), by 
calculating the Harrell’s C concordance coefficient, the time-dependant cumulative/dynamic Area under the 
ROC curve (AUC) as suggested by Chambless, L. E. and G. Diao49 and the Integrated Discrimination Index (IDI 
defined as a difference in discrimination slopes) and compared this to an algorithm that also included glycan 
predictors. We ran this analysis in the whole data set and after AJCC stage stratification. The glycan variables 
included in the final model were selected by applying generalised boosted regression, which orders the varia-
bles by their relative importance, in 1000 bootstrap samples50,51, over the 10 inner training folds, and forward 
selection of ranked glycans by applying log-likelihood ratio test. The predictive value of the models was evalu-
ated on independent samples using 10-fold cross-validation for all models except for AJCC stage 1 strata, where 
cross-validation was not possible due to the small number of events.
Finally, we performed classification analyses to a) predict whether a patient will die of CRC within 5-years 
from the time of diagnosis and b) to predict the rapid progressors within each stage. The analysis of the rapid 
progressors was pre-planned and motivated by the successful development of molecular signatures of prognostic 
biomarkers in other areas52; our goal here was to evaluate the potential of igG glycosylation as prognostic markers 
for CRC. A rapid progressor was defined as someone who died of CRC and whose follow-up time was in the lower 
1/3rd of the patients to die of CRC in that stage of cancer, with the cut-off thresholds at 2.9, 2.4, and 1.3 years for 
stages 2–4 respectively. We applied several families of classification models (LASSO, nearest neighbours, sparse 
shrunken centroids (PAM), Support Vector Machines, naive Bayes, Decision Trees, and boosted stump classi-
fiers), with and without stratification, with and without initial filtering on the training data, with and without 
log transformations of glycan expressions and clinical factors. The choice of the models was influenced by their 
popularity in biomarker studies, and their ability to address high-dimensional (large-p, small-n) problems via 
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regularization or an explicit control for model complexity. More information about these estimators is presented 
in Supplementary Box 1, and the motivations for considering multiple classifiers for this problem are discussed in 
Supplementary Section on Model Comparison. All the results for this analysis were aggregated over 10 runs using 
10-fold cross validation, where the validation folds were used neither for filtering nor for estimation of model 
parameters. Where necessary and appropriate, we also used 10 inner folds to estimate the stopping criteria or 
optimal value of hyperparameters (such as the regularization parameter for LASSO).
Then we estimated whether adding glycans to clinical covariates would improve the predictive performance 
of a model of the same class on independent test data; that is, we compared LASSO using clinical variables with 
LASSO using clinical variables and glycans, DTs using clinical variables with DTs using clinical variables and 
glycans, etc. This task is different from the association analysis, or from identifying specific glyco-clinical models 
outperforming a known baseline, where corrections for multiple tests are needed to control the probability of 
false discoveries. We applied the paired Wilcoxon sign-rank test comparing models with and without glycans, 
testing whether the difference in the cross-validated AUC of the clinical and glycol-clinical models is significantly 
different from zero. One limitation of this approach is the assumption of independence of the paired obser-
vations. (Whereas the choice of the models is independent by construction, it is difficult to ensure independ-
ence of the estimates of the performance on new, previously unused test data without constructing an extensive 
simulation study mimicking the joint distribution of the glycans and clinical variables, which goes beyond the 
scope of this paper). To address this limitation, we performed the test twice, first by considering all the models, 
and then by considering models of disparate classes, where we retained one model of each class and discarded 
SVM-linear, SVM-quadratic, and SVM-cubic differing in the degree of the polynomial used for the kernel con-
struction. We performed the tests multiple times for different training/test fold partitions of the 10-fold and 
2-fold cross-validation, and found that the results were qualitatively similar irrespectively of the specifics of 
cross-validation.
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